The collaboration is funded by the Israel-U.S. binational BIRD Foundation

The technology was developed by Prof. Simon Benita at the Hebrew University's School of Pharmacy.

Professor Itai Bab and Professor Raphael Mechoulam, from the School of Pharmacy at the Hebrew University of Jerusalem, invented a new drug candidate for the treatment of osteoporosis that both inhibits bone resorption and stimulates bone formation.

Z-Cube has received the worldwide exclusive right to develop and commercialize the technology for pain applications and will sponsor a research program to be conducted by Professor Elka Touitou from the Hebrew University's Faculty of Medicine.

Yissum announced today the appointment of Yaacov Michlin as Chief Executive Officer, effective May 1, 2009. The Company also announced that Yehuda Yarmut, who until recently was Executive Vice President Licensing & IP, was promoted and appointed Deputy Chief Executive Officer.

Merck to sponsor three-year joint R&D program with Yissum's spin-off, QLight Nanotech, for the development of novel semiconductor nanoparticles technology for optical applications

Van Leer Ventures Establishes Valensum to Develop the Technology

Professor Nissim Garti from the Casali Institute of Applied Chemistry, Institute of Chemistry at the Hebrew University of Jerusalem has received the 2009 American Oil Chemists’ Society (AOCS) Stephen S. Chang Award for his invention of novel nanoparticles of structured lipids to improve the bioavailability of various drug, food or cosmetic ingredients.

Initial cleantech inventions chosen include technologies aimed at reducing polluting effects of fossil fuels and creating alternative clean energy sources

Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, announces today that its subsidiary Jexys Pharmaceuticals has signed a strategic research and development agreement with Teva Pharmaceuticals Industries Ltd. Under the terms of the agreement, Teva will finance Jexys' R&D program for the development of a high throughput drug discovery platform and in return will receive a minority equity interest in Jexys Pharmaceuticals.

Yissum the Technology Transfer Company of the Hebrew University of Jerusalem, and BioLineRx , a clinical stage drug development company, today announced that they have signed a worldwide exclusive license agreement for BioLineRx to develop and commercialize BL-5040, a new anti-hormone for the treatment of inflammatory diseases.

Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, introduced today a novel method for real time, automatic, generic and robust pattern matching. The novel algorithm, developed by Professor Michael Werman and Ofir Pele, both from the School of Computer Science and Engineering at the Hebrew University of Jerusalem, enables very rapid recognition of a particular pattern in a fraction of the time currently available.

An international internship program has been running at Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, for the past two years. The program aims both to expand international relationships that will encourage new collaborations and to share the tech transfer knowledge and successes of Yissum’s 45 years of experience.

Technology Presented at ILSI BioMed Israel 2008 conference

The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews

cientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers.

Yissum spin-off Morria Biopharmaceuticals, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

Molecule is an antioxidant that overcomes the blood-brain barrier

Yissum announced the formation of Nanolymf, a biotechnology start up company dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.

Yissum and BioLineRx signed a worldwide exclusive license agreement for the development and commercialization of BL-4060, a small molecule drug candidate for the treatment of cancer.